Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9274971rdf:typepubmed:Citationlld:pubmed
pubmed-article:9274971lifeskim:mentionsumls-concept:C0521329lld:lifeskim
pubmed-article:9274971lifeskim:mentionsumls-concept:C0001814lld:lifeskim
pubmed-article:9274971lifeskim:mentionsumls-concept:C0066908lld:lifeskim
pubmed-article:9274971lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:9274971lifeskim:mentionsumls-concept:C0277847lld:lifeskim
pubmed-article:9274971lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:9274971lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:9274971pubmed:issue2-3lld:pubmed
pubmed-article:9274971pubmed:dateCreated1997-10-27lld:pubmed
pubmed-article:9274971pubmed:abstractTextAgmatine has been tested i.v. in alpha-chloralose anaesthetised rats for its effects on spinal nociceptive reflexes evoked by mechanical and electrical stimuli. Agmatine did not affect reflexes until very high doses (200 mg/kg, i.v.) which also caused complex cardiovascular disturbances. In spinally intact rats agmatine reduced reflexes; it was slightly less potent when there was carrageenan-induced hind paw inflammation. The alpha2-adrenoceptor antagonist atipamezole (80 microg/kg) did not significantly affect these reductions. In spinalised animals, agmatine caused a generalised increase in background firing which in animals with a non-inflamed paw was significantly reduced after atipamezole. There was no significant change in evoked responses once corrected for background activity. In all groups of animals agmatine, when administered at various doses and times prior to the mu-opioid receptor agonist fentanyl, had no effect on the ID50 of fentanyl.lld:pubmed
pubmed-article:9274971pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9274971pubmed:languageenglld:pubmed
pubmed-article:9274971pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9274971pubmed:citationSubsetIMlld:pubmed
pubmed-article:9274971pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9274971pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9274971pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9274971pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9274971pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9274971pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9274971pubmed:statusMEDLINElld:pubmed
pubmed-article:9274971pubmed:monthJullld:pubmed
pubmed-article:9274971pubmed:issn0014-2999lld:pubmed
pubmed-article:9274971pubmed:authorpubmed-author:HeadleyP MPMlld:pubmed
pubmed-article:9274971pubmed:authorpubmed-author:BradleyK JKJlld:pubmed
pubmed-article:9274971pubmed:issnTypePrintlld:pubmed
pubmed-article:9274971pubmed:day23lld:pubmed
pubmed-article:9274971pubmed:volume331lld:pubmed
pubmed-article:9274971pubmed:ownerNLMlld:pubmed
pubmed-article:9274971pubmed:authorsCompleteYlld:pubmed
pubmed-article:9274971pubmed:pagination133-8lld:pubmed
pubmed-article:9274971pubmed:dateRevised2009-9-29lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:meshHeadingpubmed-meshheading:9274971-...lld:pubmed
pubmed-article:9274971pubmed:year1997lld:pubmed
pubmed-article:9274971pubmed:articleTitleEffect of agmatine on spinal nociceptive reflexes: lack of interaction with alpha2-adrenoceptor or mu-opioid receptor mechanisms.lld:pubmed
pubmed-article:9274971pubmed:affiliationDepartment of Physiology, School of Medical Sciences, University Walk, Bristol, UK.lld:pubmed
pubmed-article:9274971pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9274971pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9274971lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9274971lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9274971lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9274971lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9274971lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9274971lld:pubmed